We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Precision Reprogrammed iPSC Models for High-Throughput Drug Discovery

Neuro Program
Credit: iStock

Despite extensive research and funding, the development of therapies to treat ALS – a progressive neurodegenerative disease – has proven challenging. Due to the scarcity of readily available human cell models, scientists have turned to animal models and cell lines that differ significantly from human biology.

Human induced pluripotent stem cell (iPSC)-derived models have the potential to provide a more clinically relevant disease phenotype; however, the process of differentiation suffers from variability, ultimately hindering scale-up for high-throughput drug discovery.

This application note showcases an ALS disease model with a genetically matched control, and how it can be used with a microelectrode array platform to observe changes in neural activity with increased throughput.


Download this app note to learn more about:

  • ALS disease progression and the models used in disease modeling
  • A breakthrough in vitro model for ALS drug development
  • A functional electrophysiological assay using this model to screen, identify and validate new drug candidates
Brought to you by

Download this App Note for FREE Below!
Information you provide will be shared with the sponsors for this content. Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.